Do you have a question or suggestion?

Fill out the form and we will contact you as soon as possible. Thank you for your interest!

     

     

    Main Contacts  Pro EuroDILINet

    General enquiries: info@proeurodilinet.eu


    Dr Raul ANDRADE
    Chair

    Prof Guruprasad AITHAL
    Vice Chair

    Dr Rossella MAGLI
    Science officer

    Ms Nathalie WARENGHIEN
    Administrative officer

    YOUNG INVESTIGATORS SEMINAR SERIES 2022

    YOUNG INVESTIGATORS SEMINAR SERIES 2022
    02/01/2018 Aurelie Papineau

    This time we will enjoy with Dr. Jorge Simon Espinosa is a postdoctoral researcher in the Liver Disease Lab from CIC bioGUNE, led by Dr. Malu Martínez-Chantar. Dr. Simon is specialized in the study of metabolic alterations that drive to liver diseases, with publications in high-impact journals such as Cell Metabolism or Journal of Hepatology. Among his works, the role of glutaminase 1 (GLS1) and cyclin M4 (CNNM4) have been elucidated as potential triggers of non-alcoholic steatohepatitis (NASH) development and progression. His current research is focused on further elucidating the role of ammonia and CNNM4-mediated magnesium perturbations in other liver diseases.

    Particularly, in the next session Dr. Simon will describe his work recently published as co-corresponding author (DOI: 10.3390/antiox11050897). There, Rodríguez-Agudo & Goikoetxea-Usandizaga et al. describe the ammonia and methionine cycle perturbations that occur during drug-induced liver injury (DILI) upon acetaminophen (APAP) overdose. They show that how the anti-miR-873-5p therapy restores the methionine cycle activity. As a consequence, ammonia homeostasis is recovered and its metabolism is rewired towards polyamines synthesis for protecting the liver against DILI.

    See the video here

    Date: 15th June 2022, at 16.30h (CEST)

    Guest: Dr. Jorge Simón Espinosa

    Our last speaker was Dr. Oleg Lunov, Ph.D., he has completed a PhD in Molecular Medicine Ulm, Germany in 2011. After, he worked as post-doctoral researcher in the Institute of Pharmacology, Ulm University, Germany. In 2014 Dr. Lunov received Purkyně fellowship and joined Institute of Physics of the Czech Academy of Sciences, Prague. From 2016 Dr. Lunov is Head of the Laboratory of Biophysics at Institute of Physics of the Czech Academy of Sciences, Prague.

    You can get more information in this web.

    See the video here. Potential of nanoparticles as livery injury agents

    Date: 18th May 2022, at 16.30h (CEST)

    Guest: Dr. Oleg Lunov

    Our speaker was Daniel Di Zeo Sánchez, although now based in Malaga, Daniel’s family background comes from a long history of international mobility across 5 different countries. He graduated in Biochemistry with a mention in Molecular and Applied Biochemistry by the University of Malaga (UMA) and University of Seville (2013-2017) and holds a master’s in Advanced Biotechnology (UMA, 2018-2019). After finishing his superior studies, he benefited from long-term grants and contracts such as a 6-months grant for studying molecular biology of cancer, and an 18-month contract in the field of microbiology.
    His most recent professional experience came at the end of 2019 when, moved for the curiosity of solving human health problems, he joined the Hepatogastroenterology, Pharmacology and Translational Clinical Therapeutics group at the Biomedical Research Institute of Malaga (IBIMA). Since then, he enrolled in the PhD programme of Biomedicine, Translational Research and New Health Technologies (UMA) to pursue his thesis project, focused on studying mechanistic and immunological features of the disease known as drug-induced liver injury, in continuous interaction with clinicians and the pharmaceutical industry.
    Daniel di Zeo Sánchez will present his experience during a 3-month Short Term Scientific Mission in the laboratory of Prof. Joana P. Miranda, at the Faculty of Pharmacy of the University of Lisbon. During this period, he worked on in vitro techniques for the study of immunological mechanisms of drugs related to idiosyncratic hepatotoxicity, using different sources of liver and immune cells as models.

    Advancing in vitro models of DILI: key techniques for the study of the inmunological features of idiosyncratic hepatotoxicity in cell cultures

    Date: 20th April 2022, at 16.30h (CEST)

    Guest: Daniel Di Zeo Sánchez

    Our speaker was Prof. Dr. . Dr. Hengstler has completed a PhD in Medical and health sciences with a specialty of DNA damage at the University of MainzI. From 2007 Dr Hengstler is Professor (W3) and Scientific Director at the Leibniz Research Centre for Working Environment and Human Factors in Dortmund.

    Functional imaging of hepatotoxicity: Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity

    Date: 16th March 2022, at 16.30h (CET)

    Guest: Prof. Dr. Jan G. Hengstler.

     

    Our speaker was Pamela Bachour El Azzi, professor at the Lebanese University, Université Saint Joseph and Université Antonine,for 7 years. She is commercial director and scientific consultant at Wepredic.

    Dr. Bachour El Azzi has completed a PhD in Biology and health sciences with a specialty of toxicology at the Université de Rennes I and the Lebanese University. The main PhD work of Dr. Bachour El Azzi was the characterization of bile acid transporters in HepaRG cells and the investigation of drug-induced cholestatic mechanisms. She studied cellular mechanisms underlying chlorpromazine-induced intrahepatic cholestasis in vitro in the presence or not of an inflammatory context.

    Drug-induced cholestasis: models, biomarkers and industrial challenges.

    Date: 16th February 2022, at 16.30h (CET)

    Guest: Pamela Bachour El Azzi

     

    Our last speaker was Ivan Capo from the University Clinical Centre of Vojvodina.

    Role of histopathology in the assessment of animal models in DILI prediction.

    Date: 21st January 2022, at 16.30h (CET)

    Guest: Ivan Capo

     

    Our speaker was Alejandro Hionides. He studied Biotechnology in the Universitat Ramon Llull in Barcelona. He did the final degree thesis in the Gold Lab in Bern, where he studied long non-coding RNAs. He did a master about Investigation in Immunology in the Universidad Complutense de Madrid, where he did the master thesis about chronic liver disease with Javier Cubero and Carlos Sanz. And now after his stay in Oslo with Dr. Gareth Sullivan, he started my PhD about the role of Tpl2 in chronic liver disease in Madrid.

    He talked about his stay in Oslo, where he performed a knockout with CRISPR-Cas9 of XBP1 and KEAP1 in iPSC (induced pluripotent stem cells).

    Date: 15th December, at 16.30h (CET)

    Guest: Alejandro Hionides

     

    Our last speaker was Lauryna Aukštikalnė, M.D., senior clinical pharmacology resident from the Lithuanian University of Health Sciences Hospital Kaunas Clinics where they give consultations on many drug related situations, including adverse drug reactions and DILI. Therefore, participation in COST Pro-EURO-DILI activities is strongly beneficial for her professional purposes. Last year, when the COVID pandemic significantly limited international internships, she still had an opportunity to participate in a Short Term Scientific Mission at the University of Malaga, Spain. In the Young Investigators Seminar Series she is going to talk about her experience during STSM and will present what they have accomplished during the stay.

    Date: 20th October, at 16.30h (CEST)

    Guest: Lauryna Aukštikalnė

     

    The speaker was Goran Bokan, MD from the UCC RS of Banja Luka.

    Future perspectives in DILI-nisation: How to save the liver?

    Date: 16th September, at 16.30h (CEST)

    Guests: Goran Bokan

     

    The speakers was Ismael Alvarez and Hao Niu from the Departments of Medicine and Pharmacology at Malaga University, IBIMA, who will be addressing an important topic on translational research in DILI

    Clinical Trials and Drug-Induced Liver Injury: what have we learnt and where can we go.

    As members of the working group on: Design and Endpoints in Clinical DILI Investigations and Trials, they have led a systematic review with meta-analysis on the treatment and prevention of DILI which may pave the way to set up an international multicentre research network to investigate the effectiveness of known and novel interventions that could improve clinical outcomes of DILI.

    Date: 15th JULY, at 16.30h (CEST)

    Guests: Ismael Alvarez, Hao Niu

     

    Our first guest was Nuria López-Alcántara who left Javier Cubero´s lab to enjoy a short term scientific-mission (STSM) in the laboratory of Oleg Lunov at the Institute of Physics in Prague (Czech Republic). She narrated her experience and learning, discussed the methods/ techniques used and what she aims to develop further in the future.

    Date: 17th JUNE, at 16.30h (CEST)

    Guest: Nuria López-Alcántara